nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—head and neck cancer	0.475	1	CbGaD
Afatinib—EGFR—Docetaxel—head and neck cancer	0.2	0.661	CbGbCtD
Afatinib—ABCG2—Fluorouracil—head and neck cancer	0.0433	0.143	CbGbCtD
Afatinib—ABCG2—Docetaxel—head and neck cancer	0.0331	0.109	CbGbCtD
Afatinib—ERBB2—duct of salivary gland—head and neck cancer	0.0295	0.44	CbGeAlD
Afatinib—ABCB1—Vinblastine—head and neck cancer	0.0145	0.0477	CbGbCtD
Afatinib—ABCB1—Docetaxel—head and neck cancer	0.0119	0.0393	CbGbCtD
Afatinib—ERBB2—exocrine gland—head and neck cancer	0.00262	0.0391	CbGeAlD
Afatinib—DYRK1A—hair follicle—head and neck cancer	0.00241	0.0359	CbGeAlD
Afatinib—ERBB2—mouth—head and neck cancer	0.00196	0.0293	CbGeAlD
Afatinib—IRAK1—hair follicle—head and neck cancer	0.00187	0.0279	CbGeAlD
Afatinib—ERBB2—neck—head and neck cancer	0.00168	0.025	CbGeAlD
Afatinib—Vandetanib—VEGFA—head and neck cancer	0.00134	0.322	CrCbGaD
Afatinib—ERBB2—saliva-secreting gland—head and neck cancer	0.00131	0.0195	CbGeAlD
Afatinib—ERBB4—saliva-secreting gland—head and neck cancer	0.00131	0.0195	CbGeAlD
Afatinib—BLK—lymphoid tissue—head and neck cancer	0.00128	0.0191	CbGeAlD
Afatinib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00122	0.0529	CcSEcCtD
Afatinib—ERBB2—connective tissue—head and neck cancer	0.0012	0.0179	CbGeAlD
Afatinib—ERBB4—epithelium—head and neck cancer	0.00114	0.017	CbGeAlD
Afatinib—ERBB2—epithelium—head and neck cancer	0.00114	0.017	CbGeAlD
Afatinib—Vandetanib—EGFR—head and neck cancer	0.00113	0.272	CrCbGaD
Afatinib—Gefitinib—EGFR—head and neck cancer	0.00107	0.258	CrCbGaD
Afatinib—PHKG2—thyroid gland—head and neck cancer	0.000888	0.0132	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—head and neck cancer	0.000879	0.0131	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—head and neck cancer	0.000846	0.0126	CbGeAlD
Afatinib—EPHA6—head—head and neck cancer	0.000817	0.0122	CbGeAlD
Afatinib—ERBB4—thyroid gland—head and neck cancer	0.000798	0.0119	CbGeAlD
Afatinib—ERBB2—thyroid gland—head and neck cancer	0.000798	0.0119	CbGeAlD
Afatinib—PHKG2—head—head and neck cancer	0.000788	0.0117	CbGeAlD
Afatinib—DYRK1A—thyroid gland—head and neck cancer	0.000769	0.0115	CbGeAlD
Afatinib—LCK—trachea—head and neck cancer	0.000736	0.011	CbGeAlD
Afatinib—BLK—lymph node—head and neck cancer	0.000724	0.0108	CbGeAlD
Afatinib—ERBB2—head—head and neck cancer	0.000708	0.0106	CbGeAlD
Afatinib—ERBB4—head—head and neck cancer	0.000708	0.0106	CbGeAlD
Afatinib—DYRK1A—head—head and neck cancer	0.000682	0.0102	CbGeAlD
Afatinib—EGFR—thyroid gland—head and neck cancer	0.000677	0.0101	CbGeAlD
Afatinib—Mucosal inflammation—Docetaxel—head and neck cancer	0.000634	0.0275	CcSEcCtD
Afatinib—Gefitinib—CYP1A1—head and neck cancer	0.000615	0.148	CrCbGaD
Afatinib—IRAK1—thyroid gland—head and neck cancer	0.000597	0.0089	CbGeAlD
Afatinib—LCK—thyroid gland—head and neck cancer	0.000582	0.00868	CbGeAlD
Afatinib—ABL1—parotid gland—head and neck cancer	0.000572	0.00853	CbGeAlD
Afatinib—PHKG2—lymph node—head and neck cancer	0.000552	0.00822	CbGeAlD
Afatinib—ABL1—saliva-secreting gland—head and neck cancer	0.000548	0.00817	CbGeAlD
Afatinib—ABL1—connective tissue—head and neck cancer	0.000504	0.00751	CbGeAlD
Afatinib—Interstitial lung disease—Docetaxel—head and neck cancer	0.000496	0.0215	CcSEcCtD
Afatinib—ERBB2—lymph node—head and neck cancer	0.000496	0.0074	CbGeAlD
Afatinib—DYRK1A—lymph node—head and neck cancer	0.000477	0.00712	CbGeAlD
Afatinib—Rhinorrhoea—Docetaxel—head and neck cancer	0.000433	0.0188	CcSEcCtD
Afatinib—ABL1—trachea—head and neck cancer	0.000423	0.00631	CbGeAlD
Afatinib—Sepsis—Fluorouracil—head and neck cancer	0.000422	0.0183	CcSEcCtD
Afatinib—EGFR—lymph node—head and neck cancer	0.00042	0.00627	CbGeAlD
Afatinib—Infestation—Hydroxyurea—head and neck cancer	0.000378	0.0164	CcSEcCtD
Afatinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000378	0.0164	CcSEcCtD
Afatinib—IRAK1—lymph node—head and neck cancer	0.000371	0.00553	CbGeAlD
Afatinib—Stomatitis—Hydroxyurea—head and neck cancer	0.000369	0.016	CcSEcCtD
Afatinib—ABL1—lymphoid tissue—head and neck cancer	0.000368	0.00549	CbGeAlD
Afatinib—LCK—lymph node—head and neck cancer	0.000362	0.00539	CbGeAlD
Afatinib—ABCG2—parotid gland—head and neck cancer	0.000361	0.00538	CbGeAlD
Afatinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000358	0.0155	CcSEcCtD
Afatinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000346	0.00515	CbGeAlD
Afatinib—ABL1—thyroid gland—head and neck cancer	0.000335	0.00499	CbGeAlD
Afatinib—Alopecia—Vinblastine—head and neck cancer	0.000329	0.0143	CcSEcCtD
Afatinib—Dry skin—Fluorouracil—head and neck cancer	0.000324	0.014	CcSEcCtD
Afatinib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000316	0.0137	CcSEcCtD
Afatinib—Sepsis—Docetaxel—head and neck cancer	0.000305	0.0132	CcSEcCtD
Afatinib—Alopecia—Hydroxyurea—head and neck cancer	0.0003	0.013	CcSEcCtD
Afatinib—ABL1—head—head and neck cancer	0.000297	0.00443	CbGeAlD
Afatinib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000284	0.0123	CcSEcCtD
Afatinib—Pneumonia—Fluorouracil—head and neck cancer	0.000274	0.0119	CcSEcCtD
Afatinib—Infestation NOS—Fluorouracil—head and neck cancer	0.000272	0.0118	CcSEcCtD
Afatinib—Infestation—Fluorouracil—head and neck cancer	0.000272	0.0118	CcSEcCtD
Afatinib—Renal impairment—Docetaxel—head and neck cancer	0.000268	0.0116	CcSEcCtD
Afatinib—Stomatitis—Fluorouracil—head and neck cancer	0.000265	0.0115	CcSEcCtD
Afatinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000265	0.0115	CcSEcCtD
Afatinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.000265	0.0115	CcSEcCtD
Afatinib—Epistaxis—Fluorouracil—head and neck cancer	0.000257	0.0111	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00025	0.0108	CcSEcCtD
Afatinib—Infection—Hydroxyurea—head and neck cancer	0.00024	0.0104	CcSEcCtD
Afatinib—Dehydration—Docetaxel—head and neck cancer	0.000237	0.0103	CcSEcCtD
Afatinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000236	0.0103	CcSEcCtD
Afatinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000234	0.0102	CcSEcCtD
Afatinib—Dry skin—Docetaxel—head and neck cancer	0.000234	0.0101	CcSEcCtD
Afatinib—Decreased appetite—Vinblastine—head and neck cancer	0.00023	0.00996	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00023	0.00995	CcSEcCtD
Afatinib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000228	0.00988	CcSEcCtD
Afatinib—Constipation—Vinblastine—head and neck cancer	0.000226	0.0098	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000225	0.00974	CcSEcCtD
Afatinib—Alopecia—Fluorouracil—head and neck cancer	0.000216	0.00936	CcSEcCtD
Afatinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000215	0.00932	CcSEcCtD
Afatinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000212	0.0092	CcSEcCtD
Afatinib—ABCG2—thyroid gland—head and neck cancer	0.000211	0.00315	CbGeAlD
Afatinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.00021	0.00909	CcSEcCtD
Afatinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000208	0.00902	CcSEcCtD
Afatinib—Fatigue—Hydroxyurea—head and neck cancer	0.000208	0.00901	CcSEcCtD
Afatinib—ABL1—lymph node—head and neck cancer	0.000208	0.0031	CbGeAlD
Afatinib—Constipation—Hydroxyurea—head and neck cancer	0.000206	0.00894	CcSEcCtD
Afatinib—Weight decreased—Docetaxel—head and neck cancer	0.000199	0.00864	CcSEcCtD
Afatinib—Pneumonia—Docetaxel—head and neck cancer	0.000198	0.00856	CcSEcCtD
Afatinib—Infestation NOS—Docetaxel—head and neck cancer	0.000196	0.00851	CcSEcCtD
Afatinib—Infestation—Docetaxel—head and neck cancer	0.000196	0.00851	CcSEcCtD
Afatinib—Renal failure—Docetaxel—head and neck cancer	0.000193	0.00837	CcSEcCtD
Afatinib—Stomatitis—Docetaxel—head and neck cancer	0.000191	0.0083	CcSEcCtD
Afatinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000191	0.00828	CcSEcCtD
Afatinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000191	0.00826	CcSEcCtD
Afatinib—Asthenia—Vinblastine—head and neck cancer	0.00019	0.00822	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000186	0.00805	CcSEcCtD
Afatinib—Epistaxis—Docetaxel—head and neck cancer	0.000185	0.00803	CcSEcCtD
Afatinib—Diarrhoea—Vinblastine—head and neck cancer	0.000181	0.00784	CcSEcCtD
Afatinib—Dizziness—Vinblastine—head and neck cancer	0.000175	0.00758	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000174	0.00755	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000173	0.00751	CcSEcCtD
Afatinib—Asthenia—Hydroxyurea—head and neck cancer	0.000173	0.0075	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—head and neck cancer	0.000173	0.00749	CcSEcCtD
Afatinib—Infection—Fluorouracil—head and neck cancer	0.000172	0.00747	CcSEcCtD
Afatinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.00017	0.00738	CcSEcCtD
Afatinib—Vomiting—Vinblastine—head and neck cancer	0.000168	0.00729	CcSEcCtD
Afatinib—Headache—Vinblastine—head and neck cancer	0.000166	0.00718	CcSEcCtD
Afatinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000165	0.00715	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—head and neck cancer	0.000165	0.00714	CcSEcCtD
Afatinib—Dizziness—Hydroxyurea—head and neck cancer	0.000159	0.00691	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000159	0.00689	CcSEcCtD
Afatinib—Nausea—Vinblastine—head and neck cancer	0.000157	0.00681	CcSEcCtD
Afatinib—Insomnia—Fluorouracil—head and neck cancer	0.000157	0.0068	CcSEcCtD
Afatinib—Alopecia—Docetaxel—head and neck cancer	0.000156	0.00675	CcSEcCtD
Afatinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000155	0.00671	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—head and neck cancer	0.000154	0.0067	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—head and neck cancer	0.000153	0.00665	CcSEcCtD
Afatinib—Vomiting—Hydroxyurea—head and neck cancer	0.000153	0.00665	CcSEcCtD
Afatinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000153	0.00662	CcSEcCtD
Afatinib—Rash—Hydroxyurea—head and neck cancer	0.000152	0.00659	CcSEcCtD
Afatinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000152	0.00658	CcSEcCtD
Afatinib—Headache—Hydroxyurea—head and neck cancer	0.000151	0.00655	CcSEcCtD
Afatinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000151	0.00654	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—head and neck cancer	0.00015	0.00652	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00015	0.0065	CcSEcCtD
Afatinib—ABCB1—epithelium—head and neck cancer	0.000149	0.00222	CbGeAlD
Afatinib—Back pain—Docetaxel—head and neck cancer	0.000148	0.00644	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—head and neck cancer	0.000148	0.0064	CcSEcCtD
Afatinib—Nausea—Hydroxyurea—head and neck cancer	0.000143	0.00621	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000137	0.00595	CcSEcCtD
Afatinib—Cough—Docetaxel—head and neck cancer	0.000134	0.00581	CcSEcCtD
Afatinib—ABCB1—trachea—head and neck cancer	0.000132	0.00196	CbGeAlD
Afatinib—ABCG2—lymph node—head and neck cancer	0.000131	0.00195	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00013	0.00563	CcSEcCtD
Afatinib—Infection—Docetaxel—head and neck cancer	0.000124	0.00539	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000123	0.00533	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—head and neck cancer	0.000123	0.00532	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—head and neck cancer	0.000122	0.00527	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000119	0.00515	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—head and neck cancer	0.000115	0.00497	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—head and neck cancer	0.000115	0.00171	CbGeAlD
Afatinib—Insomnia—Docetaxel—head and neck cancer	0.000113	0.00491	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—head and neck cancer	0.000112	0.00484	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—head and neck cancer	0.00011	0.00478	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—head and neck cancer	0.00011	0.00478	CcSEcCtD
Afatinib—Rash—Fluorouracil—head and neck cancer	0.000109	0.00474	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—head and neck cancer	0.000109	0.00474	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—head and neck cancer	0.000109	0.00472	CcSEcCtD
Afatinib—Headache—Fluorouracil—head and neck cancer	0.000109	0.00471	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000108	0.00469	CcSEcCtD
Afatinib—Fatigue—Docetaxel—head and neck cancer	0.000108	0.00468	CcSEcCtD
Afatinib—Constipation—Docetaxel—head and neck cancer	0.000107	0.00464	CcSEcCtD
Afatinib—ABCB1—thyroid gland—head and neck cancer	0.000104	0.00155	CbGeAlD
Afatinib—Nausea—Fluorouracil—head and neck cancer	0.000103	0.00447	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—head and neck cancer	9.9e-05	0.00429	CcSEcCtD
Afatinib—ABCB1—head—head and neck cancer	9.23e-05	0.00138	CbGeAlD
Afatinib—Asthenia—Docetaxel—head and neck cancer	8.99e-05	0.0039	CcSEcCtD
Afatinib—Pruritus—Docetaxel—head and neck cancer	8.86e-05	0.00384	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—head and neck cancer	8.57e-05	0.00372	CcSEcCtD
Afatinib—Dizziness—Docetaxel—head and neck cancer	8.28e-05	0.00359	CcSEcCtD
Afatinib—Vomiting—Docetaxel—head and neck cancer	7.97e-05	0.00345	CcSEcCtD
Afatinib—Rash—Docetaxel—head and neck cancer	7.9e-05	0.00342	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—head and neck cancer	7.89e-05	0.00342	CcSEcCtD
Afatinib—Headache—Docetaxel—head and neck cancer	7.85e-05	0.0034	CcSEcCtD
Afatinib—Nausea—Docetaxel—head and neck cancer	7.44e-05	0.00323	CcSEcCtD
Afatinib—ABCB1—lymph node—head and neck cancer	6.46e-05	0.000964	CbGeAlD
Afatinib—ERBB2—Immune System—STAT3—head and neck cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MAPK1—head and neck cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—head and neck cancer	1.4e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB4—Immune System—STAT3—head and neck cancer	1.38e-05	0.000108	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—MAPK1—head and neck cancer	1.37e-05	0.000107	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—PIK3CA—head and neck cancer	1.37e-05	0.000107	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BCL2—head and neck cancer	1.36e-05	0.000107	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	1.35e-05	0.000106	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—head and neck cancer	1.34e-05	0.000105	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MAPK3—head and neck cancer	1.33e-05	0.000105	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—head and neck cancer	1.33e-05	0.000104	CbGpPWpGaD
Afatinib—BLK—Immune System—STAT3—head and neck cancer	1.32e-05	0.000104	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MAPK3—head and neck cancer	1.31e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—STAT3—head and neck cancer	1.31e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—AKT1—head and neck cancer	1.31e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2L1—head and neck cancer	1.3e-05	0.000102	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PTEN—head and neck cancer	1.3e-05	0.000102	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MAPK3—head and neck cancer	1.3e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Disease—STAT3—head and neck cancer	1.29e-05	0.000101	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	1.29e-05	0.000101	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	1.29e-05	0.000101	CbGpPWpGaD
Afatinib—ERBB4—Disease—STAT3—head and neck cancer	1.27e-05	9.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MAPK1—head and neck cancer	1.27e-05	9.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—head and neck cancer	1.27e-05	9.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—head and neck cancer	1.27e-05	9.93e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—MAPK3—head and neck cancer	1.26e-05	9.92e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—AKT1—head and neck cancer	1.26e-05	9.9e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MAPK3—head and neck cancer	1.25e-05	9.84e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—head and neck cancer	1.25e-05	9.83e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2L1—head and neck cancer	1.25e-05	9.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MAPK1—head and neck cancer	1.25e-05	9.81e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—head and neck cancer	1.25e-05	9.81e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTEN—head and neck cancer	1.25e-05	9.8e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTEN—head and neck cancer	1.24e-05	9.76e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CASP8—head and neck cancer	1.24e-05	9.75e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MAPK1—head and neck cancer	1.23e-05	9.67e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—head and neck cancer	1.23e-05	9.67e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MAPK3—head and neck cancer	1.23e-05	9.66e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—head and neck cancer	1.23e-05	9.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MAPK3—head and neck cancer	1.21e-05	9.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NAT2—head and neck cancer	1.21e-05	9.52e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—MAPK1—head and neck cancer	1.2e-05	9.44e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—head and neck cancer	1.2e-05	9.44e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—head and neck cancer	1.2e-05	9.41e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTEN—head and neck cancer	1.2e-05	9.41e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MAPK1—head and neck cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PIK3CA—head and neck cancer	1.19e-05	9.32e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—MAPK3—head and neck cancer	1.19e-05	9.3e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MAPK1—head and neck cancer	1.17e-05	9.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—head and neck cancer	1.17e-05	9.19e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MAPK1—head and neck cancer	1.15e-05	9.06e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—head and neck cancer	1.15e-05	9.06e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—head and neck cancer	1.15e-05	9.02e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTEN—head and neck cancer	1.13e-05	8.86e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—MAPK1—head and neck cancer	1.13e-05	8.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH1—head and neck cancer	1.13e-05	8.84e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—TYMS—head and neck cancer	1.12e-05	8.8e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—head and neck cancer	1.12e-05	8.79e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	1.12e-05	8.77e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—head and neck cancer	1.12e-05	8.76e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTM1—head and neck cancer	1.11e-05	8.7e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK3—head and neck cancer	1.11e-05	8.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PIK3CA—head and neck cancer	1.1e-05	8.64e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—head and neck cancer	1.1e-05	8.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PIK3CA—head and neck cancer	1.09e-05	8.51e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	1.08e-05	8.48e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOTCH1—head and neck cancer	1.08e-05	8.44e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—head and neck cancer	1.07e-05	8.42e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PIK3CA—head and neck cancer	1.07e-05	8.39e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK3—head and neck cancer	1.07e-05	8.37e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL2—head and neck cancer	1.07e-05	8.37e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DPYD—head and neck cancer	1.06e-05	8.35e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CASP8—head and neck cancer	1.06e-05	8.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—head and neck cancer	1.06e-05	8.33e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—head and neck cancer	1.06e-05	8.29e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK1—head and neck cancer	1.05e-05	8.27e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP1A1—head and neck cancer	1.05e-05	8.24e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—head and neck cancer	1.05e-05	8.23e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—head and neck cancer	1.05e-05	8.21e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—PIK3CA—head and neck cancer	1.04e-05	8.19e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOTCH1—head and neck cancer	1.04e-05	8.14e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—head and neck cancer	1.03e-05	8.08e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP8—head and neck cancer	1.02e-05	8.03e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—head and neck cancer	1.02e-05	8e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PIK3CA—head and neck cancer	1.02e-05	7.98e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK1—head and neck cancer	1.02e-05	7.97e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—head and neck cancer	1.02e-05	7.96e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—head and neck cancer	1.01e-05	7.93e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—STAT3—head and neck cancer	1.01e-05	7.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—head and neck cancer	1.01e-05	7.92e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—YAP1—head and neck cancer	1.01e-05	7.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—head and neck cancer	1e-05	7.88e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PIK3CA—head and neck cancer	1e-05	7.86e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—head and neck cancer	9.95e-06	7.8e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—head and neck cancer	9.9e-06	7.77e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—head and neck cancer	9.9e-06	7.76e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—head and neck cancer	9.79e-06	7.68e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—head and neck cancer	9.75e-06	7.65e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—head and neck cancer	9.71e-06	7.62e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—head and neck cancer	9.66e-06	7.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK3—head and neck cancer	9.65e-06	7.57e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—head and neck cancer	9.58e-06	7.51e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—head and neck cancer	9.47e-06	7.43e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—head and neck cancer	9.41e-06	7.38e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—head and neck cancer	9.39e-06	7.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—head and neck cancer	9.27e-06	7.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK1—head and neck cancer	9.18e-06	7.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—head and neck cancer	9.18e-06	7.2e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—head and neck cancer	9.15e-06	7.17e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	9.13e-06	7.16e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—head and neck cancer	9.12e-06	7.15e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—head and neck cancer	9.11e-06	7.15e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—head and neck cancer	9.06e-06	7.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—head and neck cancer	9.03e-06	7.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—head and neck cancer	9e-06	7.06e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—head and neck cancer	8.98e-06	7.05e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—head and neck cancer	8.9e-06	6.98e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—head and neck cancer	8.87e-06	6.95e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—head and neck cancer	8.84e-06	6.93e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—head and neck cancer	8.81e-06	6.91e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—head and neck cancer	8.78e-06	6.89e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—head and neck cancer	8.78e-06	6.89e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—head and neck cancer	8.78e-06	6.89e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—head and neck cancer	8.74e-06	6.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK3—head and neck cancer	8.63e-06	6.77e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—head and neck cancer	8.53e-06	6.69e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK3—head and neck cancer	8.5e-06	6.67e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—head and neck cancer	8.46e-06	6.64e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—head and neck cancer	8.46e-06	6.64e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—head and neck cancer	8.46e-06	6.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—head and neck cancer	8.31e-06	6.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK1—head and neck cancer	8.21e-06	6.44e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—head and neck cancer	8.21e-06	6.44e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—head and neck cancer	8.19e-06	6.42e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—head and neck cancer	8.15e-06	6.4e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—head and neck cancer	8.13e-06	6.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK1—head and neck cancer	8.09e-06	6.34e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—head and neck cancer	8.09e-06	6.34e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—head and neck cancer	8.02e-06	6.29e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—head and neck cancer	8e-06	6.27e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—head and neck cancer	7.99e-06	6.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—head and neck cancer	7.97e-06	6.25e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—head and neck cancer	7.9e-06	6.2e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—head and neck cancer	7.83e-06	6.14e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—head and neck cancer	7.76e-06	6.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—head and neck cancer	7.73e-06	6.07e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—head and neck cancer	7.7e-06	6.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—head and neck cancer	7.56e-06	5.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—head and neck cancer	7.55e-06	5.92e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—head and neck cancer	7.55e-06	5.92e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—head and neck cancer	7.54e-06	5.91e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—head and neck cancer	7.47e-06	5.86e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—head and neck cancer	7.37e-06	5.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—head and neck cancer	7.3e-06	5.73e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—head and neck cancer	7.28e-06	5.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—head and neck cancer	7.27e-06	5.7e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—head and neck cancer	7.2e-06	5.65e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK1—head and neck cancer	7.18e-06	5.63e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—head and neck cancer	7.18e-06	5.63e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—head and neck cancer	7.17e-06	5.63e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—head and neck cancer	7.12e-06	5.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—head and neck cancer	7.06e-06	5.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—head and neck cancer	7.02e-06	5.5e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—head and neck cancer	6.97e-06	5.47e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—head and neck cancer	6.91e-06	5.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—head and neck cancer	6.89e-06	5.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—head and neck cancer	6.79e-06	5.32e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—head and neck cancer	6.75e-06	5.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK1—head and neck cancer	6.72e-06	5.27e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—head and neck cancer	6.72e-06	5.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—head and neck cancer	6.59e-06	5.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—head and neck cancer	6.59e-06	5.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—head and neck cancer	6.53e-06	5.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—head and neck cancer	6.51e-06	5.1e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—head and neck cancer	6.51e-06	5.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—head and neck cancer	6.49e-06	5.09e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—head and neck cancer	6.45e-06	5.06e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—head and neck cancer	6.25e-06	4.9e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—head and neck cancer	6.24e-06	4.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—head and neck cancer	6.23e-06	4.89e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—head and neck cancer	6.23e-06	4.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—head and neck cancer	6.22e-06	4.88e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK1—head and neck cancer	6.14e-06	4.81e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—head and neck cancer	6.06e-06	4.76e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—head and neck cancer	6.01e-06	4.71e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—head and neck cancer	5.99e-06	4.7e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—head and neck cancer	5.96e-06	4.67e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK1—head and neck cancer	5.94e-06	4.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—head and neck cancer	5.93e-06	4.65e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK1—head and neck cancer	5.92e-06	4.64e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—head and neck cancer	5.91e-06	4.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—head and neck cancer	5.83e-06	4.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—head and neck cancer	5.82e-06	4.56e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—head and neck cancer	5.77e-06	4.52e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—head and neck cancer	5.74e-06	4.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—head and neck cancer	5.74e-06	4.5e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—head and neck cancer	5.73e-06	4.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	5.68e-06	4.46e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK1—head and neck cancer	5.67e-06	4.45e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK1—head and neck cancer	5.46e-06	4.28e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—head and neck cancer	5.46e-06	4.28e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—head and neck cancer	5.45e-06	4.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—head and neck cancer	5.39e-06	4.23e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—head and neck cancer	5.33e-06	4.18e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—head and neck cancer	5.19e-06	4.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—head and neck cancer	5.15e-06	4.04e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—head and neck cancer	5.13e-06	4.03e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—head and neck cancer	5.09e-06	3.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—head and neck cancer	5.06e-06	3.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—head and neck cancer	5e-06	3.92e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—head and neck cancer	4.98e-06	3.91e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—head and neck cancer	4.93e-06	3.87e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—head and neck cancer	4.92e-06	3.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—head and neck cancer	4.88e-06	3.83e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—head and neck cancer	4.87e-06	3.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—head and neck cancer	4.77e-06	3.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—head and neck cancer	4.76e-06	3.74e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—head and neck cancer	4.75e-06	3.73e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—head and neck cancer	4.74e-06	3.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—head and neck cancer	4.7e-06	3.69e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—head and neck cancer	4.55e-06	3.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—head and neck cancer	4.41e-06	3.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—head and neck cancer	4.38e-06	3.44e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—head and neck cancer	4.37e-06	3.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—head and neck cancer	4.35e-06	3.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—head and neck cancer	4.25e-06	3.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—head and neck cancer	4.21e-06	3.3e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—head and neck cancer	4.21e-06	3.3e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—head and neck cancer	4.19e-06	3.29e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—head and neck cancer	4.17e-06	3.27e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—head and neck cancer	4.02e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—head and neck cancer	4.02e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK1—head and neck cancer	3.97e-06	3.11e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—head and neck cancer	3.87e-06	3.04e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	3.85e-06	3.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK1—head and neck cancer	3.82e-06	3e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—head and neck cancer	3.82e-06	3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—head and neck cancer	3.44e-06	2.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—head and neck cancer	3.38e-06	2.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—head and neck cancer	3.33e-06	2.61e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	3.32e-06	2.6e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—head and neck cancer	3.21e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—head and neck cancer	3.19e-06	2.5e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—head and neck cancer	3.14e-06	2.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—head and neck cancer	3.07e-06	2.41e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—head and neck cancer	2.95e-06	2.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—head and neck cancer	2.81e-06	2.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—head and neck cancer	2.71e-06	2.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—head and neck cancer	1.7e-06	1.33e-05	CbGpPWpGaD
